89,208 Shares in Bruker Co. (NASDAQ:BRKR) Bought by Stanley Laman Group Ltd.

Stanley Laman Group Ltd. bought a new stake in Bruker Co. (NASDAQ:BRKR) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 89,208 shares of the medical research company’s stock, valued at approximately $5,229,000. Stanley Laman Group Ltd. owned about 0.06% of Bruker as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. True Wealth Design LLC lifted its position in Bruker by 4,636.4% during the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock worth $36,000 after buying an additional 510 shares during the period. Eagle Bay Advisors LLC raised its holdings in shares of Bruker by 2,324.1% during the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock valued at $41,000 after buying an additional 674 shares during the period. GAMMA Investing LLC grew its stake in Bruker by 81.0% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock valued at $60,000 after purchasing an additional 388 shares in the last quarter. UMB Bank n.a. grew its stake in Bruker by 37.5% during the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 248 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new stake in Bruker during the 3rd quarter valued at approximately $73,000. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Trading Up 2.0 %

Shares of BRKR stock opened at $51.65 on Thursday. The company has a quick ratio of 0.73, a current ratio of 1.66 and a debt-to-equity ratio of 1.24. The company has a market capitalization of $7.83 billion, a PE ratio of 24.83, a price-to-earnings-growth ratio of 3.81 and a beta of 1.16. The firm has a 50 day moving average price of $57.88 and a two-hundred day moving average price of $60.77. Bruker Co. has a 12-month low of $48.07 and a 12-month high of $94.86.

Wall Street Analyst Weigh In

Several analysts have weighed in on BRKR shares. Barclays cut their target price on Bruker from $69.00 to $65.00 and set an “overweight” rating on the stock in a research note on Monday. Guggenheim restated a “buy” rating on shares of Bruker in a research note on Friday, January 17th. Citigroup reduced their price target on Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. UBS Group began coverage on Bruker in a research report on Tuesday, December 10th. They set a “neutral” rating and a $66.00 price objective for the company. Finally, TD Cowen lowered their price objective on Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research note on Wednesday, November 6th. Six equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $74.09.

Insider Activity at Bruker

In related news, CEO Frank H. Laukien purchased 100,000 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was acquired at an average cost of $50.14 per share, for a total transaction of $5,014,000.00. Following the completion of the purchase, the chief executive officer now owns 38,439,563 shares in the company, valued at approximately $1,927,359,688.82. This represents a 0.26 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 28.30% of the stock is currently owned by corporate insiders.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.